Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Induction of GD3/α1-adrenergic receptor/transglutaminase 2-mediated erythroid differentiation in chronic myelogenous leukemic K562 cells.

Ha SH, Kang SK, Choi H, Kwak CH, Abekura F, Park JY, Kwon KM, Chang HW, Lee YC, Ha KT, Hou BK, Chung TW, Kim CH.

Oncotarget. 2017 Aug 9;8(42):72205-72219. doi: 10.18632/oncotarget.20080. eCollection 2017 Sep 22.

PMID:
29069780
2.

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S.

Cell Death Dis. 2017 Aug 31;8(8):e3029. doi: 10.1038/cddis.2017.406.

PMID:
29048432
3.

CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia.

Sun Y, Zhao N, Wang H, Wu Q, Han Y, Liu Q, Wu M, Liu Y, Kong F, Wang H, Sun Y, Sun D, Jing L, Tang G, Hu Y, Xiao D, Luo H, Han Y, Peng Y.

J Cancer. 2017 Aug 23;8(14):2774-2784. doi: 10.7150/jca.18731. eCollection 2017.

PMID:
28928866
4.

Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Nath A, Wang J, Stephanie Huang R.

Mol Diagn Ther. 2017 Dec;21(6):621-631. doi: 10.1007/s40291-017-0292-x. Review.

PMID:
28698977
5.

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.

Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.

Int J Clin Oncol. 2017 Oct;22(5):972-979. doi: 10.1007/s10147-017-1141-y. Epub 2017 May 26.

PMID:
28550414
6.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.

Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7.

PMID:
28387926
7.

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.

Alikian M, Gale RP, Apperley JF, Foroni L.

Biomol Detect Quantif. 2017 Feb 14;11:4-20. doi: 10.1016/j.bdq.2017.01.001. eCollection 2017 Mar. Review.

PMID:
28331814
8.

Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats.

Wang P, Peng Y, Zhang X, Fei F, Wang S, Feng S, Huang J, Wang H, Aa J, Wang G.

Oncol Ther. 2016;4(1):117-128. doi: 10.1007/s40487-016-0022-2. Epub 2016 Jun 6.

PMID:
28261644
9.

A Suspected Case of an Alveolar Haemorrhage Caused by Dasatinib.

Sakoda Y, Arimori Y, Ueno M, Matsumoto T.

Intern Med. 2017;56(2):203-206. doi: 10.2169/internalmedicine.56.7363. Epub 2017 Jan 15.

PMID:
28090053
10.

The use of novel selectivity metrics in kinase research.

Bosc N, Meyer C, Bonnet P.

BMC Bioinformatics. 2017 Jan 5;18(1):17. doi: 10.1186/s12859-016-1413-y.

PMID:
28056771
11.

Induced protein degradation: an emerging drug discovery paradigm.

Lai AC, Crews CM.

Nat Rev Drug Discov. 2017 Feb;16(2):101-114. doi: 10.1038/nrd.2016.211. Epub 2016 Nov 25. Review.

PMID:
27885283
12.

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma.

Chang YS, Choi CM, Lee JC.

Tuberc Respir Dis (Seoul). 2016 Oct;79(4):248-256. Epub 2016 Oct 5. Review.

PMID:
27790276
13.

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

Keskin D, Sadri S, Eskazan AE.

Drug Des Devel Ther. 2016 Oct 13;10:3355-3361. eCollection 2016. Review.

PMID:
27784993
14.

An Atypical Initial Presentation of Chronic Myeloid Leukemia with Central Nervous System and Lymph Node Blast Crises.

Abuelgasim KA, Alshieban S, Almubayi NA, Alhejazi A, Jazieh AR.

Case Rep Oncol. 2016 Aug 10;9(2):415-421. eCollection 2016 May-Aug.

PMID:
27721761
15.

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS.

Onco Targets Ther. 2016 Aug 10;9:4937-57. doi: 10.2147/OTT.S102504. eCollection 2016. Review.

PMID:
27570458
16.

A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.

Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, Falini B, Ronco F, Ferrara F, De Fabritiis P, Luppi M, La Nasa G, Tedeschi A, Califano C, Fanin R, Dore F, Mandelli F, Meloni G, Foà R.

Haematologica. 2016 Dec;101(12):1544-1552. Epub 2016 Aug 11.

PMID:
27515250
17.

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.

Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE.

Cancer. 2016 Nov 15;122(21):3336-3343. doi: 10.1002/cncr.30197. Epub 2016 Aug 10.

PMID:
27509035
18.

Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy.

Tsutsui Y, Deredge D, Wintrode PL, Hays FA.

Sci Rep. 2016 Aug 2;6:30832. doi: 10.1038/srep30832.

PMID:
27480221
19.

BCR: a new target in resistance mediated by BCR/ABL-315I?

Haberbosch I, Rafiei A, Oancea C, Ottmann GO, Ruthardt M, Mian AA.

Genes Cancer. 2016 Jan;7(1-2):36-46.

PMID:
27014420
20.

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.

Emole J, Talabi T, Pinilla-Ibarz J.

Biologics. 2016 Feb 26;10:23-31. doi: 10.2147/BTT.S67844. eCollection 2016. Review.

PMID:
27013862

Supplemental Content

Support Center